BMSpep-57 hydrochloride
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C89H127ClN24O19S
- Molecular Weight:1904.63
-
Speicherung:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
IC50 & Target
IC50: 7.68 nM (PD-1/PD-L1 interaction)[1]
In Vitro
In a ELISA competition assay, BMSpep-57 inhibits PD-1/PD-L1 binding up to 98.1% 300 nM. And it shows a concentration dependent inhibition of PD-1/PD-L1 binding with an IC50 of 7.68 nM[1]. BMSpep-57 induced high levels of IL-2 at 1 μM and 500 nM concentrations in SEB-stimulated peripheral blood mononuclear cells[1]. BMSpep-57 (0.2-10 μM; 24 hours) does not show any effect on the Jurkat, CHO and HepG2 cells’ viability at the various concentrations tested[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
Appearance Solid
-
Molecular Weight 1904.63
-
Formel C89H127ClN24O19S
-
Color White to off-white
-
Sequence
{mercaptoacetic acid}-Phe-{Ala(NMe)}-Asn-Pro-His-Leu-Ser-Trp-Ser-Trp-{norleucine}-{norleucine}-Arg-Cys-Gly (Sulfide bridge:mercaptoacetic acid 1-Cys15)
-
Sequence Shortening
{mercaptoacetic acid}-F-{Ala(NMe)}-NPHLSWSW-{norleucine}-{norleucine}-RCG (Sulfide bridge:mercaptoacetic acid 1-Cys15)
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : ≥ 100 mg/mL (52.50 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies
Reinheit & Dokumentation
-
Data Sheet (304 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.5250 mL | 2.6252 mL | 5.2504 mL | 13.1259 mL |
| 5 mM | 0.1050 mL | 0.5250 mL | 1.0501 mL | 2.6252 mL | |
| 10 mM | 0.0525 mL | 0.2625 mL | 0.5250 mL | 1.3126 mL | |
| 15 mM | 0.0350 mL | 0.1750 mL | 0.3500 mL | 0.8751 mL | |
| 20 mM | 0.0263 mL | 0.1313 mL | 0.2625 mL | 0.6563 mL | |
| 25 mM | 0.0210 mL | 0.1050 mL | 0.2100 mL | 0.5250 mL | |
| 30 mM | 0.0175 mL | 0.0875 mL | 0.1750 mL | 0.4375 mL | |
| 40 mM | 0.0131 mL | 0.0656 mL | 0.1313 mL | 0.3281 mL | |
| 50 mM | 0.0105 mL | 0.0525 mL | 0.1050 mL | 0.2625 mL |
BMSpep-57 hydrochloride Related Classifications
HY-P3143A Related Classifications
Powered by Bioz